Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMS 2022 | MRD-directed trials & achieving MRD negativity in patients with high-risk multiple myeloma

Gordon Cook • 26 Aug 2022
IMS 2022
Multiple Myeloma
MASTER MIDAS RADAR

Gordon Cook, MB ChB, PhD, FRCP(Glas), FRCPath, Leeds Teaching Hospitals NHS Trust, Leeds, UK, outlines MRD-directed clinical trials in transplant-eligible multiple myeloma and discusses the impact of multi-drug post-transplant consolidation and maintenance to drive MRD negativity in patients with high-risk disease, highlighting the consequences of these strategies on quality of life (QoL). This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Gordon Cook

2:13
How immunotherapies are changing the myeloma treatment landscape & future outlooks
Gordon Cook • 28 Sep 2023
4:03
Developments in assessing frailty in patients with multiple myeloma
Gordon Cook • 28 Sep 2023
1:05
Considerations for frailty adapted treatment approaches in multiple myeloma
Gordon Cook • 28 Sep 2023
3:01
Moving towards a more dynamic strategy to determine eligibility for SCT in multiple myeloma
Gordon Cook • 26 Aug 2022

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals